[SCHEDULE 13G] CytomX Therapeutics, Inc. SEC Filing

Rhea-AI Filing Summary

OrbiMed Advisors LLC reported beneficial ownership of 8,461,500 shares of CytomX Therapeutics common stock, representing 5.4% of the class. The Schedule 13G filing states OrbiMed has shared voting and dispositive power over all reported shares and no sole voting or dispositive power. The filing identifies the reporting person as an investment adviser organized in Delaware and confirms these shares are held on behalf of other persons. The filing includes a certification that the position was not acquired to change or influence control of the issuer.

Positive

• OrbiMed Advisors LLC disclosed a beneficial ownership stake of 8,461,500 shares
• The reported stake represents 5.4% of CytomX Therapeutics' common stock, exceeding the 5% reporting threshold
• Filing certifies the position is not held to change or influence control of the issuer

Negative

• None.

Insights

Securities Analyst

TL;DR: OrbiMed holds a disclosed 5.4% stake with shared voting power; filing is a routine, material ownership disclosure.

OrbiMed Advisors LLC reports beneficial ownership of 8,461,500 common shares (5.4%), with shared voting and dispositive power and no sole control. The Schedule 13G classification and the certifying statement indicate the position is reported as passive under applicable rules rather than an intent to control. For investors, this is a material ownership disclosure because it crosses the 5% threshold that triggers public reporting requirements, but the filing contains no information about changes in holdings, transactions, or strategic plans.

Corporate Governance Expert

TL;DR: This is a standard passive investor disclosure showing institutional presence but no stated control intent.

The filing designates OrbiMed Advisors LLC as the reporting person and notes shared voting and disposition rights exercised through a management committee. The filing explicitly states the shares are held on behalf of others and includes a certification that the stake was not acquired to influence control. There are no governance actions, board nominations, or group affiliations disclosed here. As such, the filing signals institutional ownership without immediate governance implications.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

CytomX Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value $0.00001 per share

(Title of Class of Securities)

23284F105

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 23284F105

1

Names of Reporting Persons

OrbiMed Advisors LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 8,461,500.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 8,461,500.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

8,461,500.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.4 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: CytomX Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 151 Oyster Point Blvd., Suite 400 South San Francisco, California, 94080
Item 2.
(a)	Name of person filing: OrbiMed Advisors LLC
(b)	Address or principal business office or, if none, residence: 601 Lexington Avenue, 54th Floor New York, NY 10022
(c)	Citizenship: Delaware
(d)	Title of class of securities: Common Stock, par value $0.00001 per share
(e)	CUSIP No.: 23284F105
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 8,461,500
(b)	Percent of class: 5.4%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 8,461,500
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 8,461,500
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. The Reporting Person holds 5.4% of the shares of Common Stock in the aggregate on behalf of other persons who have the right to receive or the power to direct the receipt of dividends from, or proceeds from the sale of, such securities. OrbiMed Advisors LLC exercises investment and voting power over the shares of Common Stock through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares of Common Stock reported herein.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

OrbiMed Advisors LLC

Signature:	/s/ Carl L. Gordon
Name/Title:	Carl L. Gordon / Member of OrbiMed Advisors LLC
Date:	08/14/2025

FAQ

What stake did OrbiMed Advisors LLC report in CytomX (CTMX)?

OrbiMed reported beneficial ownership of 8,461,500 shares, representing 5.4% of the class.

Does OrbiMed have sole voting or dispositive power over the CTMX shares?

No. The filing states 0 sole voting power and 0 sole dispositive power; it reports shared voting and shared dispositive power for 8,461,500 shares.

Was the position reported as intended to influence control of CytomX?

No. The certification in the filing states the securities were not acquired and are not held to change or influence control of the issuer.

Who exercises the reported investment and voting power on behalf of OrbiMed?

The filing states investment and voting power is exercised through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild.

What is the filing form and date for this disclosure?

This is a Schedule 13G filing reporting ownership as of 06/30/2025; the signature is dated 08/14/2025.